Actinium to present ATNM-400 cancer data at EANM 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. QGEN
10. SPY

Go back to Actinium to present ATNM-400 cancer data at EANM 2026

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

October 16, 2026 8:30 AM EDT

Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development

Colorectal cancer data demonstrate ATNM-400's potential to enhance responses to standard-of-care therapies

Ovarian cancer data demonstrate the durable antitumor activity of ATNM-400, including in treatment-resistant models

Collectively, the findings support the broad potential of ATNM-400 as a differentiated targeted radiotherapy across multiple large solid tumor indications, both as monotherapy and in combination with existing treatments... More